| scholarly article | Q13442814 |
| P2093 | author name string | Hans-Peter Brunner-La Rocca | |
| Sema Bektas | |||
| P2860 | cites work | Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis | Q27012693 |
| Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction | Q28271905 | ||
| 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q29620107 | ||
| Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. | Q30382926 | ||
| How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review | Q33932889 | ||
| Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). | Q34269132 | ||
| Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure | Q34324771 | ||
| Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials | Q34614873 | ||
| Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials | Q35792547 | ||
| Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure | Q36267709 | ||
| Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials | Q37584696 | ||
| Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. | Q37595342 | ||
| BNP-guided therapy for chronic heart failure: anything more than just an attractive concept? | Q87639480 | ||
| ??? | Q28267062 | ||
| Novel biomarkers in cardiovascular disease: update 2010. | Q37799113 | ||
| What are the costs of heart failure? | Q37868827 | ||
| Heart failure care management programs: a review of study interventions and meta-analysis of outcomes | Q37985392 | ||
| B-type natriuretic peptide-guided chronic heart failure therapy: a meta-analysis of 11 randomised controlled trials | Q38100459 | ||
| Natriuretic peptide-guided heart failure management | Q38161695 | ||
| B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis | Q38187541 | ||
| A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods | Q38222335 | ||
| B-type natriuretic peptide-guided therapy: a systematic review | Q38235223 | ||
| BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial | Q38383948 | ||
| Improvement in left ventricular ejection fraction and reverse remodeling in elderly heart failure patients on intense NT-proBNP-guided therapy | Q38411505 | ||
| Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF. | Q38439129 | ||
| Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure | Q38443142 | ||
| Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial | Q38448978 | ||
| N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME | Q39227748 | ||
| Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome | Q39734086 | ||
| Short- and long-term mortality and hospital readmissions among patients with new hospitalization for heart failure: A population-based investigation from Italy | Q41702085 | ||
| Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality | Q42781665 | ||
| N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study | Q43156281 | ||
| Adherence to guideline-recommended adjunctive heart failure therapies among outpatient cardiology practices (findings from IMPROVE HF). | Q43183711 | ||
| N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial | Q43549494 | ||
| Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure | Q43949707 | ||
| Dose matters! Optimisation of guideline adherence is associated with lower mortality in stable patients with chronic heart failure. | Q43990213 | ||
| Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. | Q44014981 | ||
| The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. | Q44777037 | ||
| Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study | Q45119738 | ||
| Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure). | Q45800837 | ||
| BNP-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure | Q46757865 | ||
| Adding serial N-terminal pro brain natriuretic peptide measurements to optimal clinical management in outpatients with systolic heart failure: a multicentre randomized clinical trial (NorthStar monitoring study). | Q48120145 | ||
| Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study | Q48194485 | ||
| B-type natriuretic peptide-guided heart failure therapy: A meta-analysis | Q48263615 | ||
| Biomarkers in patients with acute dyspnoea: what for? | Q48436979 | ||
| Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state | Q48475908 | ||
| Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction | Q48563810 | ||
| Management of elderly patients with congestive heart failure--design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). | Q48564136 | ||
| Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy | Q48793123 | ||
| The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure | Q48971321 | ||
| PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. | Q50869983 | ||
| Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF. | Q50999983 | ||
| Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. | Q51039466 | ||
| Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT‐proBNP Guided Management of Heart Failure – SIGNAL‐HF (Swedish Intervention study – Guidelines and NT‐proBNP AnaLysis in Heart Failure) | Q51654594 | ||
| Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry | Q57628639 | ||
| Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations | Q73736775 | ||
| Cost analysis and cost-effectiveness of NT-proBNP-guided heart failure specialist care in addition to home-based nurse care | Q82424339 | ||
| Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy | Q83674478 | ||
| [Usefulness of brain natriuretic peptide levels, as compared with usual clinical control, for the treatment monitoring of patients with heart failure] | Q84623455 | ||
| P433 | issue | 2 | |
| P921 | main subject | heart failure | Q181754 |
| biomarker | Q864574 | ||
| chronic heart failure | Q11829287 | ||
| P304 | page(s) | 96-101 | |
| P577 | publication date | 2015-10-01 | |
| P1476 | title | Biomarker Guided Therapy in Chronic Heart Failure | |
| P478 | volume | 1 |
Search more.